Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Receivables - Other: 2013-2023

Historic Receivables - Other for Niagen Bioscience (NAGE) over the last 6 years, with Mar 2023 value amounting to $3.5 million.

  • Niagen Bioscience's Receivables - Other rose 52.17% to $3.5 million in Q1 2023 from the same period last year, while for Mar 2023 it was $3.5 million, marking a year-over-year increase of 52.17%. This contributed to the annual value of $3.1 million for FY2022, which is 47.62% up from last year.
  • As of Q1 2023, Niagen Bioscience's Receivables - Other stood at $3.5 million, which was up 12.90% from $3.1 million recorded in Q4 2022.
  • In the past 5 years, Niagen Bioscience's Receivables - Other registered a high of $4.0 million during Q2 2020, and its lowest value of $800,000 during Q4 2019.
  • Over the past 3 years, Niagen Bioscience's median Receivables - Other value was $2.3 million (recorded in 2022), while the average stood at $2.3 million.
  • Per our database at Business Quant, Niagen Bioscience's Receivables - Other spiked by 152.66% in 2019 and then tumbled by 44.36% in 2021.
  • Niagen Bioscience's Receivables - Other (Quarterly) stood at $800,000 in 2019, then climbed by 12.50% to $900,000 in 2020, then surged by 133.33% to $2.1 million in 2021, then soared by 47.62% to $3.1 million in 2022, then skyrocketed by 52.17% to $3.5 million in 2023.
  • Its last three reported values are $3.5 million in Q1 2023, $3.1 million for Q4 2022, and $2.4 million during Q3 2022.